Key Takeaway
Mounjaro vs Wegovy, Ozempic, Saxenda, Zepbound, and other weight loss options. Side-by-side comparison of effectiveness, cost, side effects, and dosing in 2026.
Choosing between Mounjaro and its alternatives is one of the most important decisions in medical weight loss. Each medication has different mechanisms, weight loss potential, side effect profiles, and costs. Mounjaro (tirzepatide) has produced the strongest weight loss results in clinical trials, but that doesn't automatically make it the best choice for every patient. Your medical history, insurance situation, tolerance for side effects, and personal preferences all factor in.
At FormBlends, we help patients manage these options every day. This guide provides direct, evidence-based comparisons so you can have an informed conversation with your physician about which medication fits your situation.
Overview: The Weight Loss Medication space in 2026
The current FDA-approved options for medical weight loss include:
- Tirzepatide (Mounjaro for diabetes, Zepbound for weight loss): GLP-1/GIP dual agonist
- Semaglutide (Ozempic for diabetes, Wegovy for weight loss): GLP-1 agonist
- Liraglutide (Saxenda): GLP-1 agonist, daily injection
- Phentermine-topiramate (Qsymia): Oral combination pill
- Naltrexone-bupropion (Contrave): Oral combination pill
- Orlistat (Xenical/Alli): Lipase inhibitor, blocks fat absorption
Bariatric surgery remains an option for patients with severe obesity. Let us compare Mounjaro to each of these alternatives in detail.
Mounjaro vs. Wegovy (Semaglutide 2.4 mg)
This is the comparison most patients ask about. Both are weekly injectables with strong clinical data. Check out our Zepbound weight loss timeline for detailed data.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
| Feature | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 agonist only |
| Average weight loss | 15-22.5% (dose dependent) | ~15% |
| Participants losing 20%+ | Up to 57% (15 mg) | ~33% |
| Nausea rate | 24-31% | ~44% |
| Vomiting rate | 9-12% | ~24% |
| Injection frequency | Once weekly | Once weekly |
| Titration to full dose | ~20 weeks | ~16 weeks |
| Monthly cost (brand, no insurance) | $1,050-$1,200 | $1,300-$1,400 |
| Monthly cost (compounded) | $199-$449 | $179-$399 |
| Cardiovascular outcome data | Pending (SURPASS-CVOT ongoing) | SELECT trial[1] showed 20% CV risk reduction |
Key Points
Tirzepatide produces greater average weight loss with lower nausea and vomiting rates. Semaglutide has a longer track record, established cardiovascular benefit data from the SELECT trial, and may be slightly less expensive in compounded form. Both are excellent medications. Some patients who don't respond well to one will respond better to the other .
Mounjaro vs. Ozempic (Semaglutide 1.0-2.0 mg)
Ozempic is FDA-approved for type 2 diabetes, not weight loss. But it's widely prescribed off-label for weight management.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| Feature | Mounjaro | Ozempic |
|---|---|---|
| FDA-approved for weight loss | Yes (as Zepbound) | No (off-label only) |
| Maximum dose | 15 mg | 2.0 mg |
| Average weight loss at max dose | 22.5% | ~10-14% (varies by study) |
| Insurance coverage for weight loss | Varies widely | Generally not covered for weight loss |
Ozempic's lower maximum dose (2.0 mg vs. Wegovy's 2.4 mg) means it produces somewhat less weight loss than Wegovy, and considerably less than Mounjaro. But Ozempic may be easier to obtain through insurance when prescribed for diabetes. For patients whose primary goal is weight loss, Mounjaro or Wegovy are stronger choices semaglutide for weight loss.
Mounjaro vs. Saxenda (Liraglutide 3.0 mg)
| Feature | Mounjaro | Saxenda |
|---|---|---|
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 agonist only |
| Average weight loss | 15-22.5% | ~5-8% |
| Injection frequency | Once weekly | Once daily |
| Nausea rate | 24-31% | ~39% |
| Monthly cost (brand) | $1,050-$1,200 | $1,300-$1,500 |
| Convenience | 1 injection per week | 1 injection per day |
Saxenda has largely been superseded by newer medications. It produces less than half the weight loss of tirzepatide, requires daily injections instead of weekly, and costs about the same or more. The only scenario where Saxenda might be preferred is if a patient has specific contraindications to tirzepatide or semaglutide, or if insurance covers Saxenda but not the newer options Saxenda for weight loss.
Mounjaro vs. Oral Medications (Qsymia, Contrave)
| Feature | Mounjaro | Qsymia | Contrave |
|---|---|---|---|
| Route | Weekly injection | Daily oral pill | Daily oral pill (twice daily) |
| Average weight loss | 15-22.5% | ~7-10% | ~5-6% |
| Key side effects | GI (nausea, diarrhea) | Tingling, dry mouth, constipation, cognitive effects | Nausea, headache, insomnia |
| Monthly cost (brand) | $1,050-$1,200 | $200-$250 | $200-$300 |
| Notable concerns | GI tolerability during titration | Heart rate increase. birth defects risk (topiramate) | Seizure risk. not for patients with opioid dependence |
Oral medications are significantly less effective than Mounjaro but also significantly cheaper. They may be appropriate as a first step for patients with mild to moderate obesity, as an add-on therapy, or for patients who can't tolerate or access injectable medications. But for patients seeking substantial weight loss (15%+ of body weight), tirzepatide and semaglutide are in a different category entirely .
Mounjaro vs. Bariatric Surgery
| Feature | Mounjaro | Gastric Bypass | Gastric Sleeve |
|---|---|---|---|
| Average weight loss | 15-22.5% | ~30-35% | ~25-30% |
| Invasiveness | Non-invasive (injection) | Major surgery | Major surgery |
| Reversibility | Fully reversible (stop medication) | Technically reversible but rarely done | Not reversible |
| Recovery time | None | 2-4 weeks | 2-4 weeks |
| Surgical risks | None | Infection, leaks, blood clots, nutritional deficiencies | Infection, leaks, blood clots |
| Long-term medication needed | Yes (to maintain results) | Vitamins and minerals permanently | Vitamins and minerals permanently |
| Typical cost | $2,400-$14,400/year | $20,000-$35,000 (one-time) | $15,000-$25,000 (one-time) |
Bariatric surgery remains the most effective single intervention for severe obesity. But Mounjaro's results at the highest dose are approaching gastric sleeve territory, without surgery, without general anesthesia, and without permanent anatomical changes. For patients with BMI 35 to 45, tirzepatide is increasingly viewed as a reasonable first option before considering surgery. For patients with BMI above 50 or those with severe weight-related complications, surgery may still offer the best risk-benefit ratio.
How to Choose: Decision Framework
Consider these factors when comparing your options:
- How much weight do you need to lose? For 15%+ body weight loss, tirzepatide or semaglutide are the strongest non-surgical options. For more modest goals, oral medications may suffice.
- What can you afford? If cost is the primary concern, compounded versions of tirzepatide or semaglutide offer the best value. Oral medications are cheaper but less effective.
- How do you feel about injections? If needles are a barrier, oral options exist, though they produce less weight loss. Most patients find the weekly injection is far less bothersome than expected.
- Do you have type 2 diabetes? Tirzepatide offers excellent blood sugar control alongside weight loss. This dual benefit makes it particularly compelling for patients with both conditions.
- What does your insurance cover? This practical reality often narrows the options. Work with your physician to determine which medications your plan covers and whether compounded alternatives make sense for your budget.
Frequently Asked Questions
Is Mounjaro better than Wegovy?
Mounjaro produces greater average weight loss and has lower rates of nausea and vomiting compared to Wegovy. But Wegovy has stronger cardiovascular outcome data (SELECT trial). Both are excellent medications. "Better" depends on your individual health profile, goals, and tolerance.
Can I switch from Wegovy to Mounjaro?
Yes, switching between GLP-1 medications is common. Your physician will determine the appropriate starting dose of tirzepatide based on your current semaglutide dose and response. You may still need to titrate up gradually with tirzepatide even if you were on a high dose of semaglutide .
Why would someone choose Saxenda over Mounjaro?
In most cases, there's little clinical reason to choose Saxenda over Mounjaro in 2026. The exceptions include specific insurance coverage situations, medical contraindications to tirzepatide, or patient preference for a medication with a longer track record (liraglutide has been available since 2010).
Is compounded tirzepatide as effective as brand Mounjaro?
Compounded tirzepatide contains compounded formulations of the active ingredient and should produce equivalent results when sourced from a licensed, quality-controlled compounding pharmacy. The main difference is cost and packaging, not efficacy Mounjaro cost without insurance.
Can I combine Mounjaro with other weight loss medications?
Combining tirzepatide with other GLP-1 medications isn't recommended due to overlapping mechanisms and increased risk of side effects. But some physicians may combine tirzepatide with oral medications like phentermine on a case-by-case basis. Any combination therapy should be managed by a physician .
Medical References
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
Getting Started with FormBlends
Choosing the right weight loss medication is a decision best made with a physician who understands your full medical picture. At FormBlends, we evaluate each patient individually and recommend the medication most likely to produce the best outcome for your specific situation. Whether that's tirzepatide, semaglutide, or another option, our goal is your health, not any particular prescription.
Start your free online assessment today to discuss your options with a licensed physician.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →